Regenerative Medicine Market Size is projected to reach USD 72.2 Billion by 2030, growing at a CAGR of 17.6%: Straits Research

New York, United States, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Regenerative drugs are used to repair, swap out, and regenerate tissues and organs harmed by injury, disease, or normal aging. Cell therapy treats patients with cellular elements like stem cells, autologous cells, xenogeneic cells, and others. In regenerative medicine, cells can be repaired, treatments are delivered to particular tissues or organs, self-healing is encouraged, and other things using cell therapy.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/regenerative-medicine-market/request-sample

Innovative Pipeline Candidates to Support Market Development Drives the Global Market

Regenerative medicine is increasingly used in disciplines like oncology, cardiology, and neurology, as well as treating wounds and mending tissue. Many pharmaceutical and life science companies are conducting clinical trials to establish their superiority over traditional treatment methods because the introduction of potential candidates is still in development, which will lead to the introduction of novel products and therapies in the market.

Expanding Consumer Acceptance of Cancer Immunotherapy Products Creates Tremendous Opportunities

Chemotherapy, radiotherapy, and surgery are frequently employed to treat cancer. Cancer immunotherapy using regenerative medicine has the advantage of being able to do so because naturally, hematopoietic stem or more developed cells can target and eradicate disease cells. Additionally, it facilitates a deeper understanding of cancer cells, advancing the development of effective treatments. As a result, both rising disease prevalence and rising product demand for cancer treatment will result in opportunities for market expansion.

Report Scope

Report Metric	Details
Market Size by 2031	USD 72.2 Billion
Market Size in 2022	USD 13.4 Billion
CAGR	17.6%
Historical Data	2020-2021
Base Year	2022
Forecast Period	2023-2031
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Type, By Material, By End User
Geographies Covered	North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors	Zimmer Biomet Holdings Inc., Abbvie Inc., Cryolife Inc., Stryker, Medtronic Plc, Baxter International Inc., Organogenesis Inc., Ocata Therapeutics Inc, Integra Lifesciences Holdings Corporation, Reliance Life Sciences
Key Market Opportunities	Expanding Consumer Acceptance of Cancer Immunotherapy Products
Key Market Drivers	Availability of Resources and Rising R&D Expenditures

Buy Now Full Report @ https://straitsresearch.com/buy-now/regenerative-medicine-market

Regional Analysis

Americas is the most significant shareholder in the global regenerative medicine market during the forecast period. The establishment of organizations like the American Academy of Regenerative Medicine (AARM) and the American Board of Regenerative Medicine (ABRM) for setting regulatory standards and promoting excellence in the field of regenerative medicine, as well as the 21st Century Cures Act, increased investor funding, supportive governmental policies, and other factors all helped the Americas capture the lion's share of the market. Due to the 21st Century Cures Act, the Regenerative Medicine Innovation Project (RMIP) was established. This project supports adult stem cell research and clinical trials to advance regenerative medicine, focusing on patient safety and scientific rigor. In addition, the US Food and Drug Administration and the NIH have worked closely to implement RMIP (FDA). The FDA has approved several stem cell-based therapies for clinical research over the past ten years; many of these have already begun clinical trials.

Europe is expected to grow at a higher CAGR during the forecast period. Europe also held a sizable market share due to the success of pan-European initiatives (like CHRODIS and CHRODIS PLUS), government initiatives, public and private research funders, and cooperative scientific research projects in regenerative medicine. In the UK, more than 500,000 people have received a genetic disorder diagnosis, according to a case study done by the Royal Society in 2017, the country's oldest scientific academy. In addition, one of these genetic disorders more common in the UK than others is familial hypercholesterolemia. One in 250 Americans, or 0.4% of the population, has familial hypercholesterolemia. Genetic disorders' prevalence, mortality, and lifetime risk are on the rise and are influenced by environmental factors, chromosomal damage, and gene mutations.

Key Highlights

• The global regenerative medicine market size is expected to reach USD 72.2 Billion by 2031, growing at a CAGR of 17.6% during the forecast period (2023–2031).
• Based on the type, the global regenerative medicine market is bifurcated into cell therapy, gene therapy, tissue engineering, and small molecule and biologics. The cell therapy segment is the highest contributor to the market.
• Based on the material, the global regenerative medicine market is bifurcated into synthetic, genetically engineered, and biologically derived. The biologically derived segment owns the highest market share during the forecast period.
• Based on the end-user, the global regenerative medicine market is bifurcated into hospitals, specialty centers, and academic and research institutes. The hospital segment is the highest contributor to the market during the forecast period.
• Americas is the most significant shareholder in the global regenerative medicine market during the forecast period.

Competitive Players

The global regenerative medicine market’s major key players are Zimmer Biomet Holdings Inc., Abbvie Inc., Cryolife, Inc., Stryker, Medtronic Plc, Baxter International Inc., Organogenesis Inc., Ocata Therapeutics Inc, Integra Lifesciences Holdings Corporation, Integra Lifesciences Holdings Corporation, and Reliance Life Sciences.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/regenerative-medicine-market/request-sample

Global Regenerative Medicine Market: Segmentation

By Type

• Cell Therapy
• Gene Therapy
• Tissue Engineering
• Small Molecule and Biologics

By Material

• Synthetic
• Genetically Engineered
• Biologically Derived

By End-User

• Hospitals
• Specialty Centers
• Academic and Research Institutes

By Regions

• North America
• Europe
• Asia-Pacific
• The Middle East and Africa

TABLE OF CONTENT

1. EXECUTIVE SUMMARY
2. RESEARCH SCOPE & SEGMENTATION

2. 1. Research Objectives
   2. Market Definition
   3. Limitations & Assumptions
   4. Market Scope & Segmentation
   5. Currency & Pricing Considered

3. MARKET OPPORTUNITY ASSESSMENT

3. 1. Emerging Regions / Countries
   2. Emerging Companies
   3. Emerging Applications / End Use
   4. Investment Landscape
   5. New Business Models / Revenue Streams
   6. TAM

4. MARKET TRENDS

4. 1. Drivers
   2. Market Warning Factors
   3. Latest Macro Economic Indicators
   4. Geopolitical Impact
   5. Human Factors
   6. Technology Factors

5. MARKET ASSESSMENT

5. 1. Porters Five Forces Analysis
   2. Value Chain Analysis
   3. Sales And Distribution Channel Analysis
   4. Case Study Analysis
   5. Patent Analysis
   6. M & A Agreements & Collabration Analysis

6. ESG TRENDS
7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE ANALYSIS

7. 1. Global Regenerative Medicine Market Introduction
   2. By Type

7. 2. 1. Introduction

1. 1. 1. 1. Type By Value

7. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

7. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

7. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

7. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

7. 3. By Material

7. 3. 1. Introduction

1. 1. 1. 1. Material By Value

7. 3. 2. Synthetic

1. 1. 1. 1. By Value

7. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

7. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

7. 4. By End-User

7. 4. 1. Introduction

1. 1. 1. 1. End-User By Value

7. 4. 2. Hospitals

1. 1. 1. 1. By Value

7. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

7. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

8. NORTH AMERICA MARKET ANALYSIS
   1. Introduction
   2. By Type

8. 2. 1. Introduction

1. 1. 1. 1. Type By Value

8. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

8. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

8. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

8. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

8. 3. By Material

8. 3. 1. Introduction

1. 1. 1. 1. Material By Value

8. 3. 2. Synthetic

1. 1. 1. 1. By Value

8. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

8. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

8. 4. By End-User
      1. Introduction

1. 1. 1. 1. End-User By Value

8. 4. 2. Hospitals

1. 1. 1. 1. By Value

8. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

8. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

8. 5. U.S.

8. 5. 1. By Type

1. 1. 1. 1. Introduction
            1. Type By Value
         2. Cell Therapy
            1. By Value
         3. Gene Therapy
            1. By Value
         4. Tissue Engineering
            1. By Value
         5. Small Molecule And Biologics
            1. By Value

8. 5. 2. By Material

1. 1. 1. 1. Introduction
            1. Material By Value
         2. Synthetic
            1. By Value
         3. Genetically Engineered
            1. By Value
         4. Biologically Derived
            1. By Value

8. 5. 3. By End-User

1. 1. 1. 1. Introduction
            1. End-User By Value
         2. Hospitals
            1. By Value
         3. Specialty Centers
            1. By Value
         4. Academic And Research Institutes
            1. By Value

8. 6. Canada
9. EUROPE MARKET ANALYSIS

9. 1. Introduction
   2. By Type

9. 2. 1. Introduction

1. 1. 1. 1. Type By Value

9. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

9. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

9. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

9. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

9. 3. By Material

9. 3. 1. Introduction

1. 1. 1. 1. Material By Value

9. 3. 2. Synthetic

1. 1. 1. 1. By Value

9. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

9. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

9. 4. By End-User

9. 4. 1. Introduction

1. 1. 1. 1. End-User By Value

9. 4. 2. Hospitals

1. 1. 1. 1. By Value

9. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

9. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

9. 5. U.K.

9. 5. 1. By Type

1. 1. 1. 1. Introduction
            1. Type By Value
         2. Cell Therapy
            1. By Value
         3. Gene Therapy
            1. By Value
         4. Tissue Engineering
            1. By Value
         5. Small Molecule And Biologics
            1. By Value

9. 5. 2. By Material

1. 1. 1. 1. Introduction
            1. Material By Value
         2. Synthetic
            1. By Value
         3. Genetically Engineered
            1. By Value
         4. Biologically Derived
            1. By Value

9. 5. 3. By End-User

1. 1. 1. 1. Introduction
            1. End-User By Value
         2. Hospitals
            1. By Value
         3. Specialty Centers
            1. By Value
         4. Academic And Research Institutes
            1. By Value

9. 6. Germany
   7. France
   8. Spain
   9. Italy
   10. Russia
   11. Nordic
   12. Benelux
   13. Rest Of Europe

10. APAC MARKET ANALYSIS

10. 1. Introduction
    2. By Type

10. 2. 1. Introduction

1. 1. 1. 1. Type By Value

10. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

10. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

10. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

10. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

10. 3. By Material

10. 3. 1. Introduction

1. 1. 1. 1. Material By Value

10. 3. 2. Synthetic

1. 1. 1. 1. By Value

10. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

10. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

10. 4. By End-User

10. 4. 1. Introduction

1. 1. 1. 1. End-User By Value

10. 4. 2. Hospitals

1. 1. 1. 1. By Value

10. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

10. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

10. 5. China

10. 5. 1. By Type

1. 1. 1. 1. Introduction
            1. Type By Value
         2. Cell Therapy
            1. By Value
         3. Gene Therapy
            1. By Value
         4. Tissue Engineering
            1. By Value
         5. Small Molecule And Biologics
            1. By Value

10. 5. 2. By Material

1. 1. 1. 1. Introduction
            1. Material By Value
         2. Synthetic
            1. By Value
         3. Genetically Engineered
            1. By Value
         4. Biologically Derived
            1. By Value

10. 5. 3. By End-User

1. 1. 1. 1. Introduction
            1. End-User By Value
         2. Hospitals
            1. By Value
         3. Specialty Centers
            1. By Value
         4. Academic And Research Institutes
            1. By Value

10. 6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest Of Asia-Pacific

11. MIDDLE EAST AND AFRICA MARKET ANALYSIS

11. 1. Introduction
    2. By Type

11. 2. 1. Introduction

1. 1. 1. 1. Type By Value

11. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

11. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

11. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

11. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

11. 3. By Material

11. 3. 1. Introduction

1. 1. 1. 1. Material By Value

11. 3. 2. Synthetic

1. 1. 1. 1. By Value

11. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

11. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

11. 4. By End-User

11. 4. 1. Introduction

1. 1. 1. 1. End-User By Value

11. 4. 2. Hospitals

1. 1. 1. 1. By Value

11. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

11. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

11. 5. UAE

11. 5. 1. By Type

1. 1. 1. 1. Introduction
            1. Type By Value
         2. Cell Therapy
            1. By Value
         3. Gene Therapy
            1. By Value
         4. Tissue Engineering
            1. By Value
         5. Small Molecule And Biologics
            1. By Value

11. 5. 2. By Material

1. 1. 1. 1. Introduction
            1. Material By Value
         2. Synthetic
            1. By Value
         3. Genetically Engineered
            1. By Value
         4. Biologically Derived
            1. By Value

11. 5. 3. By End-User

1. 1. 1. 1. Introduction
            1. End-User By Value
         2. Hospitals
            1. By Value
         3. Specialty Centers
            1. By Value
         4. Academic And Research Institutes
            1. By Value

11. 6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest Of MEA

12. LATAM MARKET ANALYSIS

12. 1. Introduction
    2. By Type

12. 2. 1. Introduction

1. 1. 1. 1. Type By Value

12. 2. 2. Cell Therapy

1. 1. 1. 1. By Value

12. 2. 3. Gene Therapy

1. 1. 1. 1. By Value

12. 2. 4. Tissue Engineering

1. 1. 1. 1. By Value

12. 2. 5. Small Molecule And Biologics

1. 1. 1. 1. By Value

12. 3. By Material

12. 3. 1. Introduction

1. 1. 1. 1. Material By Value

12. 3. 2. Synthetic

1. 1. 1. 1. By Value

12. 3. 3. Genetically Engineered

1. 1. 1. 1. By Value

12. 3. 4. Biologically Derived

1. 1. 1. 1. By Value

12. 4. By End-User

12. 4. 1. Introduction

1. 1. 1. 1. End-User By Value

12. 4. 2. Hospitals

1. 1. 1. 1. By Value

12. 4. 3. Specialty Centers

1. 1. 1. 1. By Value

12. 4. 4. Academic And Research Institutes

1. 1. 1. 1. By Value

12. 5. Brazil

12. 5. 1. By Type

1. 1. 1. 1. Introduction
            1. Type By Value
         2. Cell Therapy
            1. By Value
         3. Gene Therapy
            1. By Value
         4. Tissue Engineering
            1. By Value
         5. Small Molecule And Biologics
            1. By Value

12. 5. 2. By Material

1. 1. 1. 1. Introduction
            1. Material By Value
         2. Synthetic
            1. By Value
         3. Genetically Engineered
            1. By Value
         4. Biologically Derived
            1. By Value

12. 5. 3. By End-User

1. 1. 1. 1. Introduction
            1. End-User By Value
         2. Hospitals
            1. By Value
         3. Specialty Centers
            1. By Value
         4. Academic And Research Institutes
            1. By Value

12. 6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest Of LATAM

13. COMPETITIVE ASSESSMENT

13. 1. Adoption Matrix
    2. Regenerative Medicine Market Share By Manufacturers
    3. Regenerative Medicine Market Ranking By Revenue For Manufacturers
    4. Average Price By Manufacturers
    5. Vendor Footprint Analysis

14. MARKET PLAYERS ASSESSMENT

14. 1. Zimmer Biomet Holdings Inc.

14. 1. 1. Overview
       2. Business Information
       3. Revenue
       4. ASP
       5. Gross Margin
       6. Swot Analysis
       7. Recent Developmments

14. 2. Abbvie Inc.
    3. Cryolife Inc.
    4. Stryker
    5. Medtronic Plc
    6. Baxter International Inc.
    7. Organogenesis Inc.
    8. Ocata Therapeutics Inc
    9. Integra Lifesciences Holdings Corporation
    10. Reliance Life Sciences

15. RESEARCH METHODOLOGY

15. 1. Research Data

15. 1. 1. Secondary Data

1. 1. 1. 1. Major Secondary Sources
         2. Key Data From Secondary Sources

15. 1. 2. Primary Data

1. 1. 1. 1. Key Data From Primary Sources
         2. Breakdown Of Primaries

15. 1. 3. Secondary And Primary Research

1. 1. 1. 1. Key Industry Insights

15. 2. Market Size Estimation

15. 2. 1. Bottom-Up Approach
       2. Top-Down Approach
       3. Market Projection

15. 3. Research Assumptions

15. 3. 1. Assumptions

15. 4. Limitations
    5. Risk Assessment

16. APPENDIX

16. 1. Discussion Guide
    2. Customization Options
    3. Related Reports

17. DISCLAIMER

Read the full Report Description with Table of Content and Figure @ https://straitsresearch.com/report/regenerative-medicine-market/toc

Market News

• In September 2022, an Exclusive Multi-Year Co-Marketing Agreement for the HipInsight Mixed Reality System for Total Hip Replacement was announced by Zimmer Biomet and Surgical Planning Associates

News Media

Global Tissue Engineering Market Worth USD 11,526.51 million With a CAGR of 14.40%

Tissue Banking Market Grows Steadily at a CAGR of 5.83%

Have a Look at the Related Research Report

Advanced Therapy Medicinal Products (ATMP) Market: Information by Therapy Type (Cell Therapy, Gene Therapy, CAR-T Therapy, Tissue Engineered Product) and Regions—Forecast Till 2031

Cell Therapy Processing Market: Information by Offering Type (Products, Services, Software), Application (Cardiovascular Devices, Bone Repair, Neurological Disorders, Skeletal Muscle Repair, Cancer), and Region—Forecast till 2031

Natural Killer (NK) Cell Therapeutics Market: Information by Natural Killer (NK) cell Therapy Type (NK Cell Therapy (unmodified), CAR-NK Cell Therapy (modified), Indication, Pipeline Product, and Region—Forecast till 2031

Gene Delivery Technologies Market: Information by Mode (Biological, Chemical), Application (Gene Therapy, Cell Therapy, Vaccines), Method (Ex-vivo, In-vivo), and Region — Forecast till 2030

 About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter